Wednesday, 30 August, 2017 - 12:57
Race challenges big pharma mindset
Perth-based Race Oncology has achieved early success in its strategy of commercialising drugs overlooked by big pharmaceutical companies.
William Garner
Dr William Garner is a US physician, investor and entrepreneur.
Dr Garner is one of the inventors on the Bisantrene patents, originally filed by Update Pharma and now owned by Race Oncology.
He founded EGB Advisors LLC, a life sciences advisory firm whose clients have included the MD Anderson Cancer Center, the Kauffman Foundation, ChemGenex (ASX:CXS) and CoTherix. He also founded Inverseon which was merged with the ASX-listed company cBio to create Invion, serving as chief executive until May of 2013. He founded Urigen Pharmaceuticals and co-founded DelMar Pharmaceuticals (NASDAQ:DMPI).
Dr Garner was at Hoffmann La Roche in oncology medical affairs and worked as a merchant banker in New York City.
He is chair of InMed Pharmaceuticals (CSE:IN, OCTQB:IMLFF) & Isla Pharmaceuticals, and works with several of the other portfolio companies of EGB Ventures.
Dr Garner has a Master of Public Health from Harvard and received his MD degree from New York Medical College. Dr Garner did residency training in Anatomic Pathology at Columbia-Presbyterian and is a licensed physician in the State of New York.
